Abstract:Background: Tumor antigenicity and efficiency of antigen presentation jointly influence tumor immunogenicity, which largely determines the effectiveness of immune checkpoint blockade (ICB). However, the role of altered antigen processing and presentation machinery (APM) in breast cancer (BRCA) has not been fully elucidated. Methods: A series of bioinformatic analyses and machine learning strategies were performed to construct APM-related gene signatures to guide personalized treatment for BRCA patients. A single-sample gene set enrichment analysis (ssGSEA) algorithm and weighted gene co-expression network analysis (WGCNA) were combined to screen for BRCA-specific APM-related genes. The non-negative matrix factorization (NMF) algorithm was used to divide the cohort into different clusters and the fgsea algorithm was applied to investigate the altered signaling pathways. Random survival forest (RSF) and the least absolute shrinkage and selection operator (Lasso) Cox regression analysis were combined to construct an APM-related risk score (APMrs) signature to predict overall survival. Furthermore, a nomogram and decision tree were generated to improve predictive accuracy and risk stratification for individual patients. Based on Tumor Immune Dysfunction and Exclusion (TIDE) method, random forest (RF) and Lasso logistic regression model were combined to establish an APM-related immunotherapeutic response score (APMis). Finally, immune infiltration, immunomodulators, mutational patterns, and potentially applicable drugs were comprehensively analyzed in different APM-related risk groups. IHC staining was used to assess the expression of APM-related genes in clinical samples. Results: In this study, APMrs and APMis showed favorable performances in risk stratification and therapeutic prediction for BRCA patients. APMrs exhibited more powerful prognostic capacity and accurate survival prediction compared to conventional clinicopathological features. APMrs was closely associated with distinct mutational patterns, immune cell infiltration and immunomodulators expression. Furthermore, the two APM-related gene signatures were independently validated in external cohorts with prognosis or immunotherapeutic responses. Potential applicable drugs and targets were mined in the APMrs-high group. APM-related genes were further validated in our in-house samples. Conclusion: The APM-related gene signatures established in our study could improve the personalized assessment of survival risk and guide ICB decision-making for BRCA patients.

Aimp2 is A Novel Prognostic Biomarker Regulates Cell Proliferation and Apoptosis in Breast Cancer

Endobronchial band.

Biomarker Discovery To Improve Prediction Of Breast Cancer Survival: Using Gene Expression Profiling, Meta-Analysis, And Tissue Validation

Clinical Relevance and Prognostic Value of the Neuronal Protein Neuroligin 2 in Breast Cancer

Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer

A novel function of IMPA2, plays a tumor-promoting role in cervical cancer

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

Integral Membrane Protein 2A Inhibits Cell Growth in Human Breast Cancer Via Enhancing Autophagy Induction

IMPA2 blocks cervical cancer cell apoptosis and induces PTX resistance through p53-mediated AIFM2 regulation

Integration of bioinformatics and machine learning strategies identifies APM-related gene signatures to predict clinical outcomes and therapeutic responses for breast cancer patients

A novel anoikis-related gene signature predicts prognosis in patients with breast cancer and reveals immune infiltration

Identification of TIMP2 As a Prognostic Biomarker and Its Correlation with Tumor Immune Microenvironment: A Comprehensive Pan-Cancer Analysis

ITM2A as a Tumor Suppressor and Its Correlation With PD-L1 in Breast Cancer

Up-regulation of FN1, Activation of Maturation Promoting Factor and Associated Signaling Pathway Facilitates Epithelial-Mesenchymal Transition, Inhibits Apoptosis and Elevates Proliferation Rate of Breast Cancer Cells: In Silico Analysis of Microarray Datasets

Insulin-like growth factor 2 receptor is a key immune-related gene that is correlated with a poor prognosis in patients with triple-negative breast cancer: A bioinformatics analysis

Identification of SMC2 and SMC4 as prognostic markers in breast cancer through bioinformatics analysis

DPM2 serve as novel oncogene and prognostic marker transactivated by ESR1 in breast cancer

[Effect of fertilization on phenolic components and antioxidant activities of Artemisia annua].

Inositol Monophosphatase 1 (IMPA1) Promotes Triple‐negative Breast Cancer Progression Through Regulating Mtor Pathway and EMT Process

Bioinformatics, Molecular Docking and Experiments In Vitro Analyze the Prognostic Value of CXC Chemokines in Breast Cancer

Identification of PIMREG as a novel prognostic signature in breast cancer via integrated bioinformatics analysis and experimental validation